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introduction: Psychosocial dysfunction is associated with poor longitudinal course of 
depression and is not sufficiently addressed by existing pharmaceutical or psychological 
treatments. The aim of the current study is to evaluate the efficacy of a novel intervention 
designed to improve psychosocial function in depressed individuals. Impaired cognition, 
emotion processing, and social cognition appear to underlie (i.e., cause) psychosocial 
dysfunction in depression. The current treatment will target functioning in these domains 
(i.e., cognition, emotion, social cognition) with repeated training tasks, following the 
rationale that therapeutic benefits will arise in psychosocial functioning. It is expected 
that personalizing treatment by participants’ baseline functioning will enhance clinical 
efficacy, by comparison with standard treatment in which baseline functioning is not 
considered.
Methods: The study is a randomized, controlled treatment (RCT), in which the efficacy of 
a personalized and standard intervention will be compared. Sixteen treatment sessions 
will be administered over an 8-week period. These treatments are designed to improve 
cognition, emotion processing and social cognition. Assessments of psychosocial func-
tioning, as well as a number of secondary outcomes, will occur at baseline, 4 weeks 
(mid-RCT), 8 weeks (end of RCT), and in the observational period at baseline (week 
9) and 3 and 6 months post-RCT. Recruitment will commence in July 2017, including 
subjects diagnosed with major depressive disorder according to DSM-IV-TR criteria.
discussion: This research will provide new insight into the roles of cognition, emotion 
processing, and social cognition in psychosocial dysfunction in depression. In addition, 
the relative clinical efficacy of personalized versus standard treatment approaches will 
be assessed.
Ethics and dissemination: This study has been approved by the human research 
ethics committees of the Royal Adelaide Hospital and the University of Adelaide (ethics 
code: R20170611). The study has been registered with the Australia and New Zealand 
2
Knight and Baune Psychosocial Dysfunction in Depression—The CERT-D Study
Frontiers in Psychiatry | www.frontiersin.org December 2017 | Volume 8 | Article 280
Clinical Trials Registry Registration number: ACTRN12617000899347, web link: http://
www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12617000899347p. 
The results of the current study will be published in academic journals following com-
pletion of recruitment in 2019. Data will be owned and retained by the University of 
Adelaide, with access restricted to the research team responsible for the study.
Keywords: depression, cognitive training, cognitive remediation, psychosocial functioning, social cognition, 
emotion processing
introduCtion
Depression is the leading cause of mental illness worldwide, 
affecting approximately 322 million individuals (1). The illness 
is characterized by prolonged negative mood, anhedonia, and 
impaired cognition. Depressed individuals also demonstrate 
significantly impaired psychosocial function, indicated by 
diminished organizational, occupational, and social ability (2, 3). 
In addition to the substantial burden of depression on the daily 
lives of individuals (4) depression impacts on a societal level by 
reducing occupational productivity (5, 6). Established therapies 
(e.g., psychotherapy, CBT) and pharmaceutical treatments are 
costly and lead to high rates of recurrence in the long term (6). 
As a consequence, there is a clear need to develop alternative and/
or complimentary treatments for depression.
It is possible that existing treatments for depression under-
perform because they do not sufficiently address psychosocial 
functioning (2, 7). Psychosocial function can be defined 
on a micro level as our day-to-day ability to contend with 
environmental and social tasks (e.g., maintaining work and 
relationships), and on a macro level as the pursuit of significant 
life outcomes (e.g., self-actualization) (7). Previous work has 
operationalized these dimensions, such that quantitative and 
psychometrically valid assessments of psychosocial impair-
ment have been established (7–9). Psychosocial functioning 
appears to be related to a number of other functional outcomes 
(e.g., positive future outlook, ability to derive pleasure from 
life events), suggesting that psychosocial function contributes 
to mental health in general (10, 11). Psychosocial dysfunction 
is prevalent in depressed individuals and does not appear to 
improve even in patients who are symptomatically recovered 
(3). Ongoing psychosocial dysfunction may lead to recurrent 
episodes of depression, as impaired functioning negatively 
interacts with cognitive and emotional vulnerability in previ-
ously depressed individuals (2, 12–14).
Existing evidence indicates that cognitive, emotional, and 
social cognitive factors underlie deficits in psychosocial func-
tioning (11, 13–16). The proposed study follows this model, 
stipulating that improvements in cognition, emotion, and social 
cognition should flow on to psychosocial functioning. Given the 
importance of this model in the current study, the relationship 
between the three underlying domains and psychosocial func-
tioning will be explored.
Cognitive impairment
According to DSM-5 criteria the cognitive symptoms of major 
depressive disorder (MDD) are impaired decision making, 
management of attention, and coordination and maintenance of 
information in working memory (17). Research has also identi-
fied deficits in verbal ability (18), visuospatial processing (19), 
and psychomotor speed (19). The finding that cognitive deficits 
occur across multiple domains suggests that depression inter-
feres with underlying cognitive faculties, and with the coordina-
tion of cognitive subsystems, rather than interfering a specific 
modality of cognition. Our cognitive abilities are crucial to daily 
functioning, and to the severity of several cognitive difficulties 
associated with depression (e.g., hyper-sensitivity to negative 
feedback). Cognitive treatments target improvement of cold 
cognition, with the rationale that increasing functioning will 
benefit performance in hot cognitive tasks, and hence improve 
experience of everyday life, psychosocial functioning, and day-
to-day functioning. In addition, cognitive impairments may 
mutually interact with emotional and social factors to maintain 
or exacerbate depression, or lead to recurrent episodes (14, 16).
Psychosocial and cognitive impairments in depression and 
in other illnesses are associated with elevated levels of several 
inflammatory cytokines (20, 21). Research by the Baune group 
(22, 23) demonstrated that IL-8, IL-1beta, and tumor necrosis 
factor (TNF) are associated with memory, processing speed 
and motor function in the elderly. In addition, inflammatory 
C-reactive protein (CRP) may also be associated with depression 
symptoms (24), and the neurotransmitters 5HT, DA, and NE 
appear to be related to psychological stress (25). Investigating 
biomarkers for psychosocial functioning and cognitive dysfunc-
tion presents a valuable area for research, as there is potential 
for developing objective measurements of dysfunction predis-
position, for improving our understanding of the neurological 
mechanisms of depression and associated poor psychosocial 
functioning (e.g., neurotrophic theory), and for improving 
pharmacological treatments that address not only symptoms 
of depression but also psychosocial functioning and workplace 
functioning.
A large body of work has investigated the selective treatment 
of impaired cognition in depression with cognitive reme-
diation programs (2, 5, 26), which typically involve repeated 
completion of cognitive tasks over several weeks. The results 
of such programs generally reveal that patients improve on 
measures of executive, visuospatial, and verbal function (2). 
These results support the theory that repeated activation of 
brain regions via cognitive treatment increases neuroplasticity 
and improves neural function (27). Although cognitive gains 
following remediation programs are relatively consistent, the 
transfer of this benefit to occupational function, resilience, 
and psychosocial functioning are not well established (15). It is 
possible that transfer of cognitive skills does not reliably occur 
because remediation programs do not also address impaired 
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Social Cognition
Social cognition refers to the perception, identification, and 
interpretation of social information in interpersonal interaction 
(16). Maintaining function in this domain involves incorporat-
ing information from a range of social cues including prosody, 
facial expression, body language, verbal content, and theory 
of mind. Research has identified that social cognition may be 
impaired in individuals with depression, though the social 
cognitive deficit is less severe than in other psychiatric illnesses 
(e.g., schizophrenia) (37, 38). However, social cognition deficits 
in depression should not be overlooked, as issues with social 
interaction are associated with suicidality (39), and with severity 
of depression symptoms (40, 41).
Given the complexity of social interactions, it stands to rea-
son that cognitive functions (e.g., attention, processing speed) 
are crucial in maintaining fluid and adaptive social ability. 
Likewise, emotional recognition and bias play an important role 
in identification and perception of social information. Impaired 
emotion recognition may cause incorrect or biased assessment 
of social interaction, which may exacerbate depressed mood 
and lead to further negative social interactions (16). In turn, 
negative social experiences may lead to subsequent avoidance of 
interpersonal interactions, further enhancing feelings of isola-
tion and impaired mood. The interplay between social cogni-
tion, emotion, and general cognition further highlights the need 
for an integrated treatment approach. In addition, the broad 
and inter-related deficits associated with social cognitive issues 
suggest this factor contributes substantially to psychosocial 
functioning. This being said, the link between social cognition 
and psychosocial functioning has only recently been empirically 
investigated (16), and pilot data from our group suggest this 
relationship; supporting the need for the current research.
Social cognition is typically evaluated by one’s ability to read 
facial emotions (42). Depressed persons are typically impaired 
in facial affect recognition, in part due to a tendency to nega-
tively interpret facial emotions (43). A plausible explanation is 
that impaired attention and emotional interpretation may cause 
depressed individuals to focus on mood-congruent (i.e., nega-
tive) features of facial affect. Other studies of social cognition 
employ videos of social interactions, which are intended to be 
more naturalistic and contain more dynamic social features 
(i.e., body language, prosody, verbal information) (44, 45). 
These tasks emphasize theory of mind, as reliance on syntactic 
and visual information alone is insufficient to detect nuanced 
social interactions (e.g., sarcasm). Social cognition can also be 
measured with prosody tasks, in which several syntactically 
identical sentences are presented with different emotional 
intonations.
The current treatment will use an integrated approach in 
which cognitive remediation and cognitive training techniques 
are employed with cognitive, emotional, and social cognitive 
stimuli. While traditional cognitive training has been shown to 
increase psychosocial functioning (46, 47), it is expected that the 
addition of emotional and social training domains will extend 
and enhance this effect. Similar techniques have been employed 
to address emotional and social impairment in other psychiatric 
illnesses, including bipolar (48) and schizophrenia (49). The 
social cognitive skills and emotional processing, which may 
negatively interact with cognition on depression outcomes. The 
following paragraphs discuss the role of emotion processing and 
social cognition in MDD, and highlight how an integrated and 
personalized treatment approach may be critical to maximizing 
treatment outcomes.
Emotion Processing
Our experience of emotion is fundamentally linked to cogni-
tion. Evidence for this link is demonstrated at a neurological 
level by overlap in activation patterns of cognitive processes and 
emotional experience (28–30). The phenomenological parallels 
of emotion and cognition are consistent with cognitive models 
of depression (31), which stipulate that interplay between cogni-
tive vulnerability and negative emotion both lead to and sustain 
MDD. Specifically, cognitive models stipulate that attention and 
memory systems are biased to focus on negative information, 
suppress adaptive coping strategies (e.g., flexibility), and encour-
age maladaptive strategies (e.g., rumination) (32). The critical 
importance of emotion processing in coping and information 
processing supports the importance of this factor in determin-
ing overall psychosocial functioning (15).
The close overlap between emotion and cognition suggests that 
cognitive remediation should not neglect the role of emotion in 
treatment programs (33). Previous work in cognitive–emotional 
treatment has shown promising results in the implementa-
tion of working memory tasks with valenced stimuli (34, 35). 
Iacoviello et al. (35) conducted a study comparing the benefit of 
an integrated cognitive–emotional treatment task with that of a 
pure cold cognitive treatment task for subjects with MDD. The 
results showed that the integrated cognitive-emotional training 
resulted in greater reduction in depression symptoms and nega-
tive self-referential biases. By contrast, both the cold cognition 
and integrated tasks resulted in similar gains in attention and 
working memory performance. These findings are consistent 
with the notion that cognition and emotion are closely linked, 
and imply that an integrated treatment approach may result in 
broader transfer of therapeutic benefit.
Recent work by Wu et  al. (36) suggests that dysfunctional 
emotion processing may play a crucial role in the develop-
ment and maintenance of geriatric depression. The authors 
evaluated the positive effect of reminiscence therapy, in which 
older female patients with depression symptoms verbally 
recounted earlier life experiences by viewing pictures of past 
events. A clinical nurse encouraged the patient to recount these 
memories from different perspectives, and highlighted positive 
comparisons with the patients’ current lives. Posttreatment 
anxiety and depression symptoms were reduced, suggesting that 
encouraging flexible and positive retrieval of episodic memory 
may attenuate negative emotion processing. It is possible that 
emotional dysregulation may play a greater role in geriatric 
depression than in standard MDD, as the elderly often lack suf-
ficient social support and experience rapid physiological decline 
(36). Taken together, these findings suggest that older subjects 
in the current treatment may benefit from emotion processing 
training tasks focused on redressing negative social biases and 
negative self-evaluations.
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results of these studies suggest that social and emotional training 
may provide benefits in domains of daily life (e.g., occupational 
functioning). The clinical efficacy of these strategies in treating 
major depression has not yet been evaluated and is hence a 
primary interest of the current study. It is expected conducting 
remediation and training in three domains (i.e., cognition, emo-
tion processing, and social cognition) will improve psychosocial 
functioning to greater extent than is achieved by treating cogni-
tion alone.
Personalization
Given the multifaceted nature of impairment in depression, it 
is reasonable to assume that deficits will not occur in a uniform 
nature within individuals. Certain individuals may be disad-
vantaged specifically in domains of emotional processing, while 
others are more disadvantaged in terms of cold cognitive ability 
or social cognition. Previous interventions may not have led to 
consistent improvements in psychosocial functioning because 
individual differences in domain-specific impairment were not 
addressed. In fact, existing interventions assume that group 
means (i.e., norms) reflect impairment at an individual level, 
and hence that a generalized treatment approach is sufficient. 
Given the heterogeneity of impairment observed between indi-
viduals with MDD (12), it is possible that a standard treatment 
approach is not optimal (50). In particular, standard treatment 
approaches may misappropriate resources and time to clinical 
domains which are not relevant or helpful to the individual. In 
contrast, personalized approaches tailor treatment by targeting 
baseline deficits within individuals, enabling treatment to focus 
on impaired domains, while also spending less time address-
ing more functional domains. Personalization may improve 
treatment efficiency and efficacy, in contrast to the traditional 
standard approach.
The current investigation will evaluate the personalized 
approach, by comparing psychosocial functioning following a 
personalized intervention and a standard (i.e., non-personalized) 
intervention. The personalized intervention will tailor treatment 
tasks around baseline individual deficits, such that the indi-
vidual’s most impaired domains receive the greatest attention. 
Given the importance of cognition, emotion processing, and 
social cognition in determining psychosocial functioning, the 
CERT-D treatment will be tailored by patterns of impairment 
observed in these three domains. For example, a participant who 
demonstrates severe cognitive impairment will receive a greater 
number of treatment sessions devoted to cognition, with fewer 
sessions devoted to emotion processing and social cognition. 
Overall, it expected that both personalized and standard treat-
ments will result in improved psychosocial functioning, which 
is expected to be retained over a 6-month observational period. 
However, it is predicted that the clinical effect on psychosocial 
function will be greater following personalized, relative to stand-
ard, treatment.
In summary, the cognitive and emotional recovery training 
program for depression (CERT-D) study will evaluate a novel 
treatment for depression, employing an integrated cognitive, 
emotional and social cognitive approach. The primary outcome 
will be change in psychosocial function over the intervention 
and subsequent observational period. Performance in several 
secondary domains will also be evaluated, including depres-
sion symptom severity, resilience, occupational functioning, 
cognitive failures, and functional disability. In addition, the 
study will examine biomarkers of cognitive and psychosocial 
dysfunction in depression, providing an opportunity to expand 
our knowledge of this domain. This research will advance 
the field by evaluating the efficacy of integrating training of 
cold cognition with emotion processing and social cognition. 
The integrated approach contrasts with traditional cognitive 
remediation, which has primarily focused on the improvement 
and application of executive training. In addition, the current 
methods allow evaluation of the relative clinical efficacy of per-
sonalized and standard treatment approaches in remediating 
psychosocial dysfunction in MDD.
MEtHodS
objectives
The primary objective of the CERT-D is to evaluate whether treat-
ing cognition, emotion processing, and social cognition leads to 
immediate and longitudinal benefit in psychosocial functioning. 
To achieve this objective, participants will complete either a 
personalized or standard (non-personalized) treatment devoted 
to increasing performance in these domains. Participants in the 
personalized group will receive a tailored treatment incorporat-
ing a greater number of sessions devoted to their domain(s) of 
primary baseline dysfunction. By contrast, the standard treat-
ment group will complete a pre-established battery of treatment 
independent of baseline deficits.
The key hypotheses and aims of the current study are as follows:
Hypothesis 1: Overall, psychosocial functioning will be improved 
at 8 weeks [end of randomized, controlled treat-
ment (RCT)] relative to baseline. Psychosocial 
functioning in the observational period (post-
RCT) will not decline at 3 and 6 months relative 
to post-RCT baseline.
Related Aim: To evaluate which subdomains of psychosocial 
function (e.g., autonomy, social relationships) are 
sensitive to change over time from the CERT-D.
Hypothesis 2: Performance in secondary outcome measures 
will improve at 8 weeks relative to baseline, and 
will be retained over a 6-month observational 
period. Secondary outcomes include occupatio-
nal functioning, cognitive failures, functional 
disability, resilience, and depression symptom 
severity.
Hypothesis 3: It is expected that the personalized treatment group 
will display greater psychosocial improvement at 
8 weeks (compared to baseline) than subjects who 
complete a standard treatment.
Hypothesis 4: Biological and genomic signatures will be asso-
ciated with psychosocial functioning, as well as 
cognitive, emotional, and social cognitive perfor-
mance.
FigurE 1 | Clinical timeline for the CERT-D. Participants will complete 2 training sessions per week (16 sessions total) over the 8-week intervention period.
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Study design and recruitment
The CERT-D study will commence in July 2017. The study will 
be a RCT, comparing the clinical efficacy of a personalized and 
standard intervention. Psychosocial functioning is considered 
the primary outcome. An effect size of approximately d = 0.5 is 
expected with regards to change in psychosocial function over 
the intervention. Given the intended sample size of 100, the study 
will achieve statistical power of 89% (1 − β = 89). The rationale 
for this “medium” effect size is that previous interventions have 
found positive outcomes approximate to this magnitude (5, 35), 
for example in cognitive functioning.
The trial will include 16 treatment sessions designed to 
improve cognition, emotion processing, and social cognition 
administered over an 8-week period. Assessments will occur at 
baseline, 4 weeks (mid-RCT), 8 weeks (end of RCT), and in the 
observational period at baseline (week 9) and 3 and 6 months 
post-RCT (see Figure 1). Assessments will measure psychosocial 
functioning, cognition, emotional state, social cognition, as well 
as occupational functioning, depression symptom severity, 
functional disability, cognitive failures, and resilience. Three 
assessment visits will also include taking blood for biomarker 
and genetic analysis. Recruitment will include individuals 
between the ages of 18 and 75, who will be invited to participate 
via research clinics of the Department of Psychiatry, University 
of Adelaide, and within the Central Health Network in Adelaide, 
South Australia. It could be argued that the age range should 
be restricted to younger adults (<60), such that subjects with 
geriatric depression are excluded. However, recent work has 
suggested that cognitive training strategies are efficacious in the 
treatment of geriatric depression (47, 51, 52). Given the current 
intervention shares many components of traditional cognitive 
training, it is suggested that the CERT-D intervention should 
benefit older (i.e., 60–75 years) patients.
inclusion and Exclusion Criteria
Individuals with mild–moderate MDD according to DSM-IV-TR 
criteria (17) will be recruited for the current study. Severely 
depressed subjects will not be included, as the complexity from 
treatment tasks would likely result high rates of deterrence. 
Subjects identified through screening with bipolar or anxiety 
disorders will be excluded, as will subjects with schizophrenia, a 
learning disorder, eating disorder or a pervasive developmental 
disorder. Subjects with current brain injury or impairment which 
could affect cognitive function (e.g., neurodevelopmental disor-
ders, dementia) will be excluded. In addition, subjects will be 
withdrawn following subsequent severe brain/head injury, devel-
opment of dementia, psychosis, or development of neurological 
conditions such as multiple sclerosis or Parkinson’s disease.
Ethics
The CERT-D has been approved by the Human Research Ethics 
Committees at the Royal Adelaide Hospital (approval number: 
R20170611) and The University of Adelaide (approval number: 
R20170611). All details of participant involvement will be con-
veyed to study participants both in writing and verbally before 
informed consent is obtained.
There are no severe adverse effects expected to result from 
the current treatment. However, participants will be withdrawn 
from treatment if they demonstrate a significant increase in 
depression symptom severity [20% increase in Montgomery 
Asberg Depression Rating Scale (MADRS) score] and referred 
to their treating psychiatrist or GP.
randomization Process
After screening, subjects will be randomly allocated with com-
puter software to receive either personalized or standard (non-
personalized) treatment (see Figure  2). In both the standard 
and personalized intervention groups each treatment session 
will consist of domain-specific tasks. Every treatment session 
will be repeated at least once, to ensure that subjects have the 
opportunity to practice the treatment tasks.
Personalized treatment
Personalized interventions will be tailored to address subjects’ 
most impaired domains. Domain-specific tests will be admin-
istered at baseline to determine the modality and degree of 
individual impairment. On the basis of baseline deficits, subjects 
in the personalized group will be allocated to one of four potential 
treatment arms; (1) high cognition treatment, (2) high emotion 
treatment, (3) high social cognition treatment, and (4) broad 
FigurE 2 | CERT-D randomization process. Several streams of treatment 
are available for subjects in the personalized group (high cognition, high 
emotion, high social cognition, broad impairment), whereas treatment is the 
same for every participant in the standard treatment group.
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impairment treatment (see Figure 2). Subjects will be allocated to 
streams 1, 2, or 3 if impairment is primarily represented in one of 
the three baseline domains. In treatment arms, 1–3 subjects will 
complete a greater number of intervention sessions devoted to the 
domain of primary dysfunction. Subjects who are significantly 
impaired in two or more domains will be allocated to broad 
impairment treatment. Broad impairment treatments will incor-
porate a similar number of intervention sessions in each domain, 
but will be initiated more gradually (i.e., initial treatment sessions 
will be shorter in duration) and will use simpler tasks.
Standard treatment
Subjects allocated to the standard (i.e., non-personalized) inter-
vention will receive an identical intervention regardless of base-
line impairment. The standard intervention will be comprised 
of approximately an equal number of treatment sessions in each 
domain. Unlike broad impairment treatment, standard treat-
ment sessions will be the full duration from the outset and the 
difficulty curve of treatment tasks will be steeper.
CliniCal, SElF-rEPort, and 
CognitiVE aSSESSMEntS
Screening
Participants will be screened for presence of MDD with the MINI 
600 Neuropsychiatric Diagnostic Interview. The MINI is well 
validated and has demonstrated high specificity and sensitivity, 
as well as close concordance with the American Psychiatric 
Association Diagnostic Criteria (SCID), and the Composite 
International Diagnostic Interview (ICD-10) (53, 54). The 
MADRS will also be administered as a measure of depression 
symptom severity (55).
assessment Visits (Baseline—6 Months 
Post-rCt)
In total, six assessments of functioning and performance will 
occur over the CERT-D timeline (see Figure  1). In the inter-
vention period, subjects will complete assessments at baseline, 
4 weeks (mid-RCT), and 8 weeks (end of RCT). The observational 
period will comprise assessments in week 9 (baseline post-RCT), 
as well as 3 and 6 months post-RCT.
Psychosocial Functioning
Psychosocial functioning will be assessed with the Functioning 
Assessment Short Test (FAST); a clinician administered 24-item 
scale. The FAST includes questions which gauge subjects’ abilities 
across several psychosocial domains of daily living (e.g., auton-
omy, leisure, financial issues). The FAST takes approximately 
6  min to complete (9) and will be administered by a clinician 
blind to experimental group allocation.
Cognitive Functioning
Cognitive functioning will be assessed with the THINC-it tool; 
a digitally administered screening instrument for cognitive 
impair ment in depression. The THINC-it involves four objec-
tive tests of cognitive performance, including choice reaction 
time, a 1-back memory task, the Trail Making Test Part B and 
digit symbol substitution. The THINC-it also includes a 5-item 
component of the self-reported perceived deficit questionnaire, 
as an indication of retrospective cognitive dysfunction (56).
Emotion
Participants’ emotional state will be assessed with the Positive 
and Negative Affect Schedule (PANAS), which requires subjects 
to indicate the intensity of current and recent emotions. Scores 
are calculated separately for positive and negative emotions, with 
higher scores indicating greater intensity. The separability of posi-
tive and negative mood scores enables discriminate bilateral mood 
evaluation, which is not possible with unilateral scales or with 
measures of depression symptom severity alone. The PANAS has 
well-supported psychometric properties, including high internal 
consistency and convergent and discriminant validity (57, 58).
Social Cognition
The Weschler Adult Intelligence Scale Advanced Clinical 
Solutions Social Cognition Test (WAIS-IV-ACS) will be used 
to assess participants’ social cognition. This component of the 
WAIS was developed in response to the finding that memory for 
faces and affect recognition was independent of other cognitive 
abilities, suggesting a unique neuropsychological construct in 
social cognition (38). The test involves three tasks designed to 
identify social cognitive impairment: Affect Naming, Prosody-
Face Matching, and Prosody-Pair Matching.
Depression Symptom Severity
Depression symptom severity will be assessed with the MADRS 
and the Structured Interview Guide of the Hamilton Anxiety and 
Depression Scale (SIGH-AD). The SIGH–AD is a 31-item struc-
tured interview that combines the Hamilton Depression Scale 
(HAM-D, 17 items) and the Hamilton Anxiety Scale (HAM-A, 
14 items) (59).
Work Productivity
Two scales will be used to evaluate occupational functioning: 
The Endicott Work Productivity Scale (EWPS) and the Work 
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Productivity and Impairment Questionnaire (WPAI). Both the 
EWPS and WPAI are self-report questionnaires designed to 
measure occupational productivity (60, 61). Importantly the 
EWPS measures overall occupational impairment, whereas 
the WPAI measures the extent to which a particular issue 
(e.g., depression) negatively affects occupational functioning.
Resilience
Resilience will be assessed with “The Resilience Scale” (62). 
The scale involves completing a 26-item Likert scale, of which 
each item makes a broad statement measuring the participants’ 
perceived resilience (e.g., “I usually manage one way or another”). 
The Resilience Scale has shown high internal consistency and 
concurrent validity (63), as well as validation with a number of 
age and ethnic groups (64).
Functional Disability
Disability in daily life will be evaluated with the Sheehan 
Dis ability Scale (65, 66). This will involve participants self-
reporting the extent to which depression symptoms disrupt 
three domains: (1) work/school, (2) social life, and (3) family 
life/home responsibilities. The Sheehan disability scale achieves 
high internal consistency (0.89) and concurrent validity, with 
high scores are indicative of mental health disorders (65).
Cognitive Failures
Cognitive failures can be defined as everyday slips of memory 
and attention (e.g., forgetting a colleague’s name). The current 
study will evaluate cognitive failures with the Cognitive Failures 
Questionnaire (CFQ), which gages the frequency of cognitive 
failures experienced in the past 6 months. The CFQ appears to 
have acceptable construct validity, as factor analysis has indicated 
that CFQ items load primarily to a single construct (67).
Blood Specimen
Blood taking will occur at baseline, week 8 (end of RCT), and 
at 6  months post-RCT. These samples will enable analyses of 
biomarker associations with psychosocial functioning, as well 
as the effect of the CERT-D intervention on biomarker levels. 
Blood serum analyses will include of evaluation of cytokine 
concentration (e.g., IL-8, TNF), CRP levels, and neurotransmit-
ter activity. Samples will be stored in secure refrigerators with 
stringent access rights at the Adelaide Health and Medical 
Sciences building.
CErt-d intErVEntion dEtailS
The intervention is comprised of 16 total treatment sessions. 
Each session will be devoted to one of the underlying domains of 
psychosocial functioning targeted by the CERT-D (i.e., cognition, 
emotion processing, social cognition). Tasks completed within 
sessions will be presented in both digital and pen and paper 
formats. Several digital tasks will be completed with the psychol-
ogy experiment building language (PEBL) software (68), which 
incorporates a number of freely distributed psychological tests 
presented in a game-like manner. Other treatment tasks will be 
administered in a pen and paper format.
Cognition treatment
Cognition treatment sessions will involve cold cognition tasks, 
with the expectation that subjects’ performance in these tasks 
will improve over time. The researcher will emphasize the value 
of cold cognitive skills in everyday life and discuss transfer of 
these skills to functional domains (e.g., psychosocial function-
ing). Each cognition session will focus on one of three cognitive 
modalities: Executive functioning, visuospatial working memory, 
and verbal working memory (69). Executive treatment sessions 
will focus on attention, inhibition, problem solving and mental 
updating (70). Executive tasks include Berg’s card sorting test, 
symbol counting, and the Stroop task (68). Visuospatial treat-
ment sessions will focus on spatial learning, mental rotation, and 
spatial coordination (71), including map learning (72), figure 
learning, Corsi blocks (73), and matrix rotation tasks (68). Verbal 
treatment sessions will target verbal sequencing, reading span, 
and digit span (74). Verbal training will utilize immediate and 
delayed verbal memory tasks in the SCIP battery (75), and the 
reading span and digit span tests in PEBL (68).
Emotion Processing treatment
The aim of emotion processing sessions will be to address negative 
emotional biases and cognitive-emotional (i.e., “hot cognition”) 
impairment in depression. Training tasks will attempt to increase 
participants’ performance in hot cognitive tasks, in which 
depressed patients typically underperform (34). In addition, the 
subject will be encouraged to discuss any cognitive–emotional 
issues which arise in these training sessions, which the expecta-
tion that raising awareness and understanding may help subjects 
cope with and overcome emotional dysfunction (e.g., emotional 
avoidance, poor reappraisal) (32). Emotional treatment tasks 
include emotional brain storming (49), an emotional n-back (35), 
and emotion word list tasks (76). Taken together, these tasks are 
intended to embed emotional stimuli within traditional cognitive 
remediation techniques (e.g., the n-back task). These strategies 
are based on the rationale that improving cognitive management 
and processing of emotional material will reduce negative atten-
tional and cognitive biases in subjects with MDD (35).
Social Cognition treatment
Social cognitive training sessions will involve targeting per-
formance in domains of facial affect recognition, prosody 
detection, body language, and interpersonal communication. 
Taken together, it is intended that social cognitive treatment will 
improve subjects’ ability to synthesize a broad spectrum of social 
information, make clearer theory of mind judgments, and reduce 
social tension and avoidance. The researcher will emphasize the 
importance of social cognition in everyday life and encourage 
participants to exercise acquired social skills outside of treatment 
sessions. Social cognition training tasks will include a “reading 
the mind in the eyes” task (77), an interpersonal word list task 
(78) and theory of mind scenarios (44, 45). These tasks are 
designed to improve the evaluation of facial affect, verbal tone, 
and body language, while also highlighting the pitfalls of making 
unfounded or overly negative assumptions about others’ inten-
tions and emotions.
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intErVEntion outCoMES, analySES, 
and diSSEMination
The primary outcome of the CERT-D will be psychosocial func-
tioning. Specifically, it is expected that psychosocial functioning 
will improve at 8 weeks (end of RCT) relative to baseline. Post-
RCT psychosocial functioning is expected to be maintained over 
the 6  months observational period. Performance in secondary 
outcome measures is expected to demonstrate a similar effect 
of treatment. Secondary outcomes include depression symptom 
severity, occupational functioning, resilience, functional disabil-
ity, and perceived cognitive failures. In addition, the personal-
ized treatment group is expected to show greater improvement 
over time relative to the standard treatment group. Finally, the 
association between biomarkers and psychosocial and cognitive 
performance before and following treatment will be evaluated.
Statistical analyses will be performed with a mixed model 
ANOVA with time (baseline, 8  weeks, baseline post-RCT, 
3  months post-RCT, 6  months post-RCT) and treatment type 
(personalized, standard) as independent variables. Psychosocial 
functioning (FAST score) will be the dependent variable. It is 
expected that overall psychosocial functioning will improve at 
post-treatment relative to baseline, and that this improvement 
will be greater in the personalized treatment arm relative to the 
standard treatment arm. Biomarker analyses require specifically 
tailored software and will ultimately be entered into simple and 
stepwise linear regression analyses. These analyses will determine 
whether individual biomarkers (e.g., CRP), or combinations of 
biomarkers, are related to cognition (i.e., THINC-it performance) 
or psychosocial functioning.
Within the personalized treatment group, further analyses 
will evaluate whether there are any differences in psychosocial 
functioning owing to the domain-specific treatment groups. 
That is, will there be any differences in post-RCT psychosocial 
functioning between the high cognition, high emotion, and high 
social cognition treatment groups? Given the novelty of the cur-
rent treatments, these analyses will be exploratory. As with the 
primary outcome, analyses for this outcome will be conducted 
with mixed model ANOVAs.
The anonymized data obtained in the current study will be 
owned by the University of Adelaide, with access restricted to 
the research team responsible for the project. The results of the 
CERT-D study will be published in scientific journals, which will 
discuss clinical efficacy of personalized and standard approaches 
in light of the data obtained. The authors will also conduct a public 
lecture to discuss the broader topic of personalized psychiatry, 
which will include dissemination of outcomes in the current study.
diSCuSSion
Existing literature suggests that psychosocial functioning is 
associated with depression severity and with longitudinal treat-
ment outcomes (2, 3). Mutual interaction between psychosocial 
domains (e.g., work productivity, socializing) in depressed 
persons may exacerbate, maintain, or lead to recurrent depres-
sion. As an example, poor cognitive functioning may lead to 
issues maintaining work, which will cause financial strain and 
lead to reduced social interactions and impaired affect. Given the 
importance of psychosocial functioning in depression recovery, 
the development of treatments designed to target psychosocial 
functioning is justified.
Current research by the Baune group suggests that cognitive, 
emotional, and social cognitive domains underpin psychosocial 
functioning (12, 16). The CERT-D will target these domains with 
repeated training sessions over an 8-week intervention period. 
Cognitive and cognitive–emotional treatment approaches for 
depression have received empirical support (2, 32, 35). Initial 
research suggests treating social cognition may also be beneficial 
(16, 79, 80); however, further evidence is needed to establish the 
efficacy of treating social cognitive functioning in depression. 
The CERT-D study addresses this gap in knowledge by evaluating 
a treatment approach integrating all three underlying domains 
of psychosocial functioning (i.e., cognition, emotion process-
ing, and social cognition). Treatment benefits of the CERT-D 
are intended to transfer to occupational functioning, resilience, 
functional abilities, and cognitive performance. Reinforcing 
improved performance and positive interaction between these 
domains is expected to develop a framework which encourages 
and rewards reduction of depression symptoms.
The directionality of recovery in the CERT-D is divergent 
from traditional depression therapies. That is, existing therapies 
(e.g., psychotherapy) target reduction in negative depression 
symptoms with the expectation that improvements in functional 
and psychosocial domains will follow. By contrast, the current 
treatment targets psychosocial and functional improvements 
from the outset. Importantly, the CERT-D integrates treatment 
across cognitive, emotional, and social domains rather than 
focusing on one of these domains alone. Integrating treatment 
across multiple domains is intended to counteract negative 
feedback between impaired domains which may occur in more 
selective treatments.
A possible disadvantage of administering training across three 
domains is that treatment benefits to cold cognitive functioning 
(e.g., executive functioning) will be attenuated in comparison 
to traditional cognitive remediation. Reduced executive gains 
in the CERT-D treatment could result from the equal emphasis 
given to social, emotional, and cognitive domains, as opposed to 
focusing purely on cold cognition. However, we do not anticipate 
this issue to be a crucial issue for two key reasons: (1) emotional 
and social–cognitive training demand similar cognitive effort 
and are equally complex in comparison to traditional cognitive 
training. As a result, emotional and social training may also 
benefit executive functioning. (2) Individuals who demonstrate 
significantly impaired cold cognition will be allocated to the 
“High Cognition” program within the personalized arm. This 
treatment program emphasizes cognitive treatment above emo-
tional and social domains, and will hence evaluate the efficacy 
of predominantly cognitive training, relative to training all three 
domains in the “standard” treatment group. If cognition training 
alone is identified as having greater clinical efficacy than the inte-
grated training approach, then this finding will also contribute to 
the value of the current study.
In summary, the CERT-D will make three primary contribu-
tions: (1) the evaluation of a novel psychological treatment for 
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depression. Psychosocial function is considered the primary 
outcome, and is expected to be improved by integrated treatment 
of underlying domains. (2) The comparison of the relative clini-
cal efficacy of personalized and standard treatment approaches. 
Taking baseline deficits into account may enable more efficient 
and effective psychosocial recovery, as impaired domains receive 
greater attention. In combination, contributions (1) and (2) 
may lead to the development of an intervention which could be 
conducted in parallel or in lieu of other treatments for depression. 
(3) The current study will also improve our understanding of the 
genomic, neurological and biological correlates of psychosocial 
and cognitive dysfunction in depression. Taken together, these 
findings will advance the field of personalized psychiatry by 
evaluating the relative efficacy of a standard and personalized 
treatment approach, in addition to testing the overall value of 
targeting psychosocial deficits in MDD.
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